Multiple Myeloma

Latest News

July 7th 2023

MAIA Trial: DRd vs Rd in Transplant-Ineligible Patients with MM

By Al-Ola Abdallah, MD, Leyla O. Shune, MD, Nausheen Ahmed, MD

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

Latest Videos

Samer A. Al'Hadidi, MD, with Rahul Gosain, MD, and Rohit Gosain, MD

Advice for Community Oncologists Treating R/R Multiple Myeloma

Treatment Decision-Making in Relapsed/Refractory Multiple Myeloma

Adverse Effect Management for CAR T-Cell Therapy and Bispecifics in R/R MM

The Role of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Monitoring Patients with Relapsed/Refractory Multiple Myeloma

Caitlin Costello, MD, with the Oncology Brothers

Key Takeaways on Optimizing Multiple Myeloma Care

Maintenance Therapy in Patients with Multiple Myeloma

Monitoring Induction Therapy & MRD in Multiple Myeloma

Tailoring Treatment for Patients with Multiple Myeloma

The Role of Biomarkers in Diagnosing Multiple Myeloma

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Iowa Oncology Society

Marla D. Lipsyc-Sharf, MD; Sheila Donnelly, MD

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Texas Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Parth Khade, MD

Video

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Virtual Event

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma

ByC. Ola Landgren, MD, PhD,Dickran Kazandjian, MD,Benjamin Diamond, MD,Dennis Verducci, APRN

July 7th 2023

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

Relapsed/Refractory MM: Safety and Efficacy Data From MonumenTAL-1

ByAjai Chari, MD,Carolina D. Schinke, MD

July 6th 2023

Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.

MonumenTAL-1 in Relapsed/Refractory MM: Overview of Study Design

ByAjai Chari, MD,Carolina D. Schinke, MD

July 6th 2023

Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.

Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

ByBinod Dhakal, MD, MS,Joseph R. Mikhael, MD,Cindy Varga, MD,Beth Faiman, PhD, CNP,Jeremy Larsen, MD

July 5th 2023

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Future Perspectives on the Role of Bispecifics in MM

ByBinod Dhakal, MD, MS,Joseph R. Mikhael, MD,Cindy Varga, MD,Beth Faiman, PhD, CNP,Jeremy Larsen, MD

July 5th 2023

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

July 5th 2023

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Experts Spotlight Some of The ‘Biggest Concerns’ In Multiple Myeloma

ByAl-Ola Abdallah, MD,Nausheen Ahmed, MD,Leyla O. Shune, MD,Jordan Snyder, PharmD

July 4th 2023

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Bispecifics in MM: Future Directions in Care

ByRafael Fonseca, MD,Shaji Kumar, MD, Mayo Clinic,Joselle Cook, MBBS, Mayo Clinic,Morie A. Gertz, MD, MACP, Mayo Clinic

July 4th 2023

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Long-Term Monitoring for CRS and AEs With Bispecific Therapy

ByCesar Rodriguez, MD,Scott A. Soefje, PharmD,Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC,Frances A. Bell, NP

July 4th 2023

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Selecting Patients for BCMA and Non-BCMA Bispecifics in Multiple Myeloma

ByRafael Fonseca, MD,Shaji Kumar, MD, Mayo Clinic,Joselle Cook, MBBS, Mayo Clinic,Morie A. Gertz, MD, MACP, Mayo Clinic

July 4th 2023

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics

ByCesar Rodriguez, MD,Scott A. Soefje, PharmD,Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC,Frances A. Bell, NP

July 4th 2023

Expert perspectives on ensuring the early detection and treatment of CRS and other adverse events when initiating bispecific therapy in patients with multiple myeloma.

Updated Results of the MonumenTAL-1 Study in R/R MM

ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD

July 3rd 2023

Noffar Bar, MD, details data on talquetamab in R/R MM treatment from the MonumenTAL-1 study, and Syed S. Ali, MD, speaks to his experience with teclistamab in clinical practice.

Available Treatment Options for Patients With R/R MM

ByNatalia Neparidze, MD,Noffar Bar, MD,Elan Gorshein, DO, JD, MPH,Catherine Wei, MD,David Witt, MD,Syed S. Ali, MD

July 3rd 2023

Elan Gorshein, DO, JD, MPH, explains his choice of frontline therapy for patients with relapsed/refractory multiple myeloma.

Optimizing Treatment Strategies in Relapsed/Refractory Multiple Myeloma

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 30th 2023

A panel of experts shares insight on treatment sequencing and selection in the setting of relapsed/refractory multiple myeloma.

Frontline Treatment Regimens in the Setting of Transplant-Ineligible NDMM

ByAndrew P. Dalovisio, MD,Kelly Pippin, MD,Ryan P. Griffin, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD

June 30th 2023

Experts from Ochsner Health highlight treatment options for patients who present with transplant-ineligible newly diagnosed multiple myeloma.

MM: Managing Adverse Effects from Bispecific Antibodies

ByC. Ola Landgren, MD, PhD,Dickran Kazandjian, MD,Benjamin Diamond, MD,Dennis Verducci, APRN

June 30th 2023

Experts on multiple myeloma discuss the management of adverse effects from bispecific antibodies.

Maintenance Therapy Considerations for Standard- and High-Risk MM

ByAl-Ola Abdallah, MD,Leyla O. Shune, MD,Nausheen Ahmed, MD,Jordan Snyder, PharmD

June 30th 2023

Experts on multiple myeloma offer clinical insights on treatment options and considerations for patients with standard- and high-risk multiple myeloma.

Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

ByC. Ola Landgren, MD, PhD,Dickran Kazandjian, MD,Benjamin Diamond, MD,Dennis Verducci, APRN

June 30th 2023

An expert panel discusses bispecific antibodies and their mechanisms of action in the treatment of relapsed/refractory multiple myeloma.

Measuring Treatment Response Following Induction Therapy in Patients with MM

ByAl-Ola Abdallah, MD,Leyla O. Shune, MD,Nausheen Ahmed, MD,Jordan Snyder, PharmD

June 30th 2023

Nausheen Ahmed, MD, discusses the measurement of treatment response following induction therapy in patients with multiple myeloma.

Investigators anticipate sharing data from a phase 1/2a trial evaluating inobrodib on its own and in combination with pomalidomide and dexamethasone among patients with multiple myeloma at a future medical conference.

Inobrodib Receives FDA Orphan Drug Designation in Multiple Myeloma

ByRuss Conroy

June 29th 2023

Investigators anticipate sharing data from a phase 1/2a trial evaluating inobrodib on its own and in combination with pomalidomide and dexamethasone among patients with multiple myeloma at a future medical conference.

Data appear to support a tailored treatment approach with induction and post–autologous stem cell transplant consolidation daratumumab and CVRd in those with ultra-high–risk multiple myeloma.

Daratumumab/CVRd Yields PFS Benefit in Ultra-High-Risk Multiple Myeloma

ByRuss Conroy

June 29th 2023

Data appear to support a tailored treatment approach with induction and post–autologous stem cell transplant consolidation daratumumab and CVRd in those with ultra-high–risk multiple myeloma.

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

Curability, Maintenance Therapy, and Unmet Needs in Multiple Myeloma

ByAndrew P. Dalovisio, MD,Ernest C. Quintin, MD,Thomas Atkinson, MD,Kelly Pippin, MD,Ryan P. Griffin, MD

June 28th 2023

A recent Satellite Sessions program hosted by CancerNetwork® brought together experts from different Ochsner Health campuses to discuss the diversity of practices among care providers regarding patient interactions and treatment choices.

Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment

ByBinod Dhakal, MD, MS,Joseph R. Mikhael, MD,Cindy Varga, MD,Beth Faiman, PhD, CNP,Jeremy Larsen, MD

June 28th 2023

Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.

Recent Data on Non-BCMA Targeting Bispecifics in R/R MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 28th 2023

Experts review recent data on non-BCMA-targeting bispecifics for the treatment of R/R MM.

Selecting and Sequencing Non-BCMA-Targeting Bispecifics in MM

BySurbhi Sidana, MD,Melissa Alsina, MD, Maria-Victoria Mateos, MD, PhD,Jack Khouri, MD

June 28th 2023

The panel discusses how non-BCMA-targeting bispecifics might be selected and sequenced in MM.